tcsc0888 Duvelisib

Duvelisib is a selectivite p100δ inhibitor with IC₅₀ of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.

IC50 & Target: IC50: 2.5 nM (p110δ), 27.4 nM (p110γ), 85 nM (p110β), 1602 nM (p110α)^[2]

In Vitro: PI3Kδ and PI3Kγ inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells^[1].